{"version":"1.0","type":"link","title":"From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.","author_name":"Gaudio M 외","author_url":"https://prs-insight.online/author/Gaudio%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/87124","thumbnail_width":1200,"thumbnail_height":630}